{"id": "20221028_10-K_320193_part2_item7_para7", "text": "in april 2022, the company announced an increase to its program authorization from $315 billion to $405 billion and raised its quarterly dividend from $0.22 to $0.23 per share beginning in may 2022. during 2022, the company repurchased $90.2 billion of its common stock and paid dividends and dividend equivalents of $14.8 billion.", "highlight": "increase to its program authorization from $315 billion to $405 billion and raised its quarterly dividend from $0.22 to $0.23 per share beginning in may 2022 ||| repurchased $90.2 billion of its common stock and paid dividends and dividend equivalents of $14.8 billion.", "type": {"0": 0, "1": 0, "2": 1, "3": 0, "4": 0}, "topic": {"1": 0, "2": 0, "3": 0, "4": 0, "5": 0, "6": 0, "7": 2, "0": 0}}
{"id": "20220318_10-K_1045810_part2_item7_para5", "text": "Recent developments, future objectives and challenges Termination of the arm share purchase agreement on february 8, 2022, nvidia and softbank announced the termination of the share purchase agreement whereby nvidia would have acquired arm from softbank. the parties agreed to terminate because of significant regulatory challenges preventing the completion of the transaction. we intend to record in operating expenses a $1.36 billion charge in the first quarter of fiscal year 2023 reflecting the write-off of the prepayment provided at signing in september 2020.", "highlight": "nvidia and softbank announced the termination of the share purchase agreement whereby nvidia would have acquired arm from softbank ||| because of significant regulatory challenges preventing the completion of the transaction", "type": {"0": 0, "1": 0, "2": 1, "3": 0, "4": 0}, "topic": {"1": 0, "2": 0, "3": 0, "4": 0, "5": 0, "6": 1, "7": 0, "0": 0}}
{"id": "20220217_10-K_200406_part2_item7_para42", "text": "on january 28, 2022, subsequent to the fiscal year 2021, additional information regarding efficacy became available which led the company to the decision to terminate the development of bermekimab for atopic dermatitis (ad). the company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (jnj-77474462), an investigational drug for the treatment of ad and hidradenitis suppurativa (hs). the impairment charge is related to the ad indication and is a nonrecognized subsequent event and will be reflected in the first quarter 2022 financial statements. the company acquired all rights to bermekimab from xbiotech, inc. in fiscal year 2020.", "highlight": "terminate the development of bermekimab for atopic dermatitis (ad) ||| the company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab", "type": {"0": 0, "1": 0, "2": 1, "3": 0, "4": 0}, "topic": {"1": 0, "2": 0, "3": 0, "4": 0, "5": 0, "6": 1, "7": 0, "0": 0}}
{"id": "20220216_10-K_1585689_part2_item7_para74", "text": "in response to the global crisis resulting from the covid-19 pandemic, we took certain proactive measures in 2020 to help our business withstand the negative impact on our business from the crisis. these measures included securing our liquidity position to be able to meet our obligations for the foreseeable future, including issuing senior notes, drawing down the available borrowing capacity of our $1.75 billion revolving credit facility and consummating the april 2020 pre-sale of hilton honors points to american express for $1.0 billion in cash (the \"honors points pre-sale\"). further, in february 2021, we issued the 3.625% senior notes due 2032 to continue to extend debt maturities and reduce our cost of debt by repaying the outstanding 5.125% senior notes due 2026. based on our continued recovery and expectations of the foreseeable demands on our available cash and our liquidity in future periods, we had fully repaid the outstanding debt balance on the revolving credit facility by june 2021.", "highlight": "covid-19 pandemic ||| securing our liquidity position to be able to meet our obligations for the foreseeable future, including issuing senior notes, drawing down the available borrowing capacity of our $1.75 billion revolving credit facility and consummating the april 2020 pre-sale of hilton honors points to american express for $1.0 billion in cash ||| we issued the 3.625% senior notes due 2032 to continue to extend debt maturities and reduce our cost of debt by repaying the outstanding 5.125% senior notes due 2026", "type": {"0": 0, "1": 0, "2": 1, "3": 0, "4": 0}, "topic": {"1": 0, "2": 0, "3": 0, "4": 0, "5": 0, "6": 1, "7": 0, "0": 0}}
{"id": "20220222_10-K_1090727_part2_item7_para5", "text": "in october 2021, we completed the acquisition of roadie, a technology platform focused on same-day delivery services, for $586 million. the results of roadie are reported within supply chain solutions. the acquisition did not have a material impact on our results of operations for the year. see note 9 to the audited, consolidated financial statements for additional information on this transaction.", "highlight": "we completed the acquisition of roadie, a technology platform focused on same-day delivery services, for $586 million |||  the acquisition did not have a material impact on our results of operations for the year.", "type": {"0": 0, "1": 0, "2": 1, "3": 0, "4": 0}, "topic": {"1": 0, "2": 0, "3": 0, "4": 0, "5": 0, "6": 1, "7": 0, "0": 0}}
